Retatrutide

[GavinParkPT]

Retatrutide is an experimental drug developed by Eli Lilly and Company for the treatment of obesity and type 2 diabetes. It is a triple hormone receptor agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Here are some key points about Retatrutide:

What is Retatrutide?
Function: It works by activating three different hormone receptors to help regulate appetite, insulin secretion, and glucose metabolism.

Benefits: Early clinical trials have shown promising results, including significant weight loss and improved glycemic control.

Clinical Trial Results
Phase 2 Trial: Retatrutide achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity or overweight. In a secondary endpoint, it demonstrated up to 24.2% weight reduction at 48 weeks.

Safety: The drug has been well-tolerated in clinical trials, with mild side effects such as nausea and injection site reactions.

Administration
Dosage: Typically administered as a once-weekly injection.

Consultation: It's important to consult with a healthcare professional before starting any new treatment.

Current Status
FDA Approval: Retatrutide is still under investigation and has not yet received FDA approval.

Ongoing Research: Eli Lilly is advancing Retatrutide through phase 3 clinical trials to further evaluate its efficacy and safety